In western countries, approximately 50% of the CRC patients were firstly diagnosed after 70 years old. It was reported that in 1980s, the median age of CRC diagnosis in China was 50. However, in 2005 it had reached 58 years old and has kept increasing in recent years. Limited by age-related organ function decline and comorbid conditions, elderly people shows impaired physical and mental tolerance for chemotherapy. Generally for stage II/III CRC patients, both elderly and younger patients shares common principles of chemotherapy, while a large-scale retrospective analysis based on the ACCENT database showed that among all the CRC cases included, patients with the age ≥ 70 only accounted for 17.1%, much lower than normal. Similarly, Shrag and colleagues reported in their investigation that the proportion of patients ≥75 years old undergoing chemotherapy was substantially lower than patients ≤ 75 years old. These evidence implied that elderly CRC patients held much lower acceptance and completion rate of chemotherapy. With respect to outcomes, a pooled analysis including 3351 CRC cases with adjuvant chemotherapy reported no significant difference on both efficacy and adverse effects among groups of various age, indicating elderly patients could achieve the same benefits from adjuvant chemotherapy. Thus, it is essential to improve the acceptance and completion rate by modifying chemotherapy regimen for elderly CRC patients to achieve better prognosis. There was no random controlled trial focusing on the adjuvant chemotherapy for stage II/III elderly CRC patients.